PDHB

PDHB encodes the E1β subunit of the mitochondrial pyruvate dehydrogenase complex (PDC), which assembles with E1α into an α2β2 heterotetramer to catalyze the oxidative decarboxylation of pyruvate to acetyl-CoA, the committed entry of glycolytic carbon into the TCA cycle (PMID:11724561, PMID:19924563). Recessive loss-of-function missense mutations in PDHB reduce E1β immunoreactivity and abolish PDC activity, causing primary PDH complex deficiency that can present as Leigh syndrome; complementation with wild-type PDHB restores enzyme activity in patient fibroblasts, and structural and stability analyses show that pathogenic substitutions disrupt inter-subunit contacts and K+ ion coordination required for tetramer assembly, with E1β destabilization in turn destabilizing E1α (PMID:15138885, PMID:18164639, PMID:19924563, PMID:40050878). The complex is stabilized post-translationally through physical interaction of PDHB with the prolyl-hydroxylase PHD3, which is required to maintain functional PDC and cellular PDH activity (PMID:25088999), while a mitochondrial PDH phosphatase reactivates the phosphorylated, inactive complex (PMID:6300332). Beyond its canonical catalytic role, PDHB is a node in metabolic reprogramming: its levels are durably reduced under prolonged hypoxia to sustain a glycolytic Warburg-like state, and PDHB is itself regulated by miR-146b-5p and stabilized through interaction with OGDHL, with manipulation of PDHB altering glycolysis, acetyl-CoA/ATP output, and tumor growth in breast, colorectal, gastric, and hepatocellular cancers (PMID:29436427, PMID:28560062, PMID:39922943, PMID:41420718). In hepatocellular carcinoma PDHB binds the promoters of glycolytic genes (SLC2A1, GPI, PKM2) to drive their transcription (PMID:39922943), and during TGFβ-driven endoderm differentiation PDHB-supplied ATP supports BRG1/BAF chromatin remodeling and endodermal gene programs (PMID:41702907). Neuronal knockdown of Drosophila PDHB impairs lifespan, locomotion, neuromuscular junction morphology, and mitochondrial integrity, underscoring its requirement for neuronal energy metabolism (PMID:29501567).

1. 2001 High

   The structural basis for how E1β assembles and what stabilizes the catalytic core was unknown; the archaeal E1β crystal structure defined the GPhiXXG helix-helix motif mediating the E1α–E1β interface and showed E1β rearranges and self-associates in the absence of E1α.

   Evidence X-ray crystallography of archaeal E1β with light scattering and analytical ultracentrifugation, compared to human and P. putida heterotetramers

   PMID:11724561

   Open questions at the time

   • Structure is of an archaeal ortholog, not human PDHB
   • Does not address regulation of assembly in cells
   • Catalytic mechanism within the assembled tetramer not resolved
2. 2004 High

   Whether PDHB mutations directly cause PDH deficiency rather than being incidental variants was unresolved; complementation of patient fibroblasts with wild-type PDHB restored PDC activity, establishing PDHB loss-of-function as a direct genetic cause.

   Evidence Mutation sequencing, immunoblot for E1β, and functional complementation by wild-type PDHB transfection in patient fibroblasts

   PMID:15138885

   Open questions at the time

   • Per-mutation structural mechanism not defined
   • Does not address tissue-specific phenotype variability
3. 2008 Medium

   How specific PDHB point mutations cause deficiency was unclear; a mutation series with structural modeling showed pathogenic substitutions disrupt inter-subunit contacts and K+ coordination needed for E1β stability and α2β2 assembly, and confirmed recessive inheritance.

   Evidence PDHB sequencing, PDC activity assays in lymphocytes and fibroblasts, immunoblot, and computational structural modeling

   PMID:18164639

   Open questions at the time

   • No in vitro reconstitution of mutant assembly
   • Modeling not validated by experimental structures of mutants
4. 2009 Medium

   Whether E1β instability affects the partner subunit was unknown; PDHB mutations causing Leigh syndrome reduced both E1α and E1β protein levels, demonstrating that E1β destabilization collapses the entire E1 heterodimer.

   Evidence PDHB sequencing, PDHc/E1 activity assays in fibroblasts and muscle, immunoblot for E1α and E1β

   PMID:19924563

   Open questions at the time

   • No complementation performed
   • Mechanism of co-degradation not defined
5. 2025 Medium

   Continued discovery of pathogenic alleles; the c.575G>T (p.Arg192Leu) variant was shown to reduce PDHB stability and PDH activity in cells, confirming pathogenicity.

   Evidence Whole exome sequencing plus recombinant expression of wild-type and mutant PDHB in 293T cells with Western blot and PDH activity assay

   PMID:40050878

   Open questions at the time

   • Single patient, single mutation
   • Stability mechanism not structurally resolved
6. 1983 Medium

   The enzyme reactivating the phosphorylated PDC and its location were unresolved; PDHb phosphatase was localized to mitochondria and shown to dephosphorylate and activate inactive phospho-PDH in a Mg2+/Ca2+-dependent manner.

   Evidence Subcellular fractionation of rat brain with marker enzymes, phosphatase activity assay on purified phospho-PDH substrate, kinetic and inhibitor studies

   PMID:6300332

   Open questions at the time

   • Performed in rat brain, not human
   • Does not address regulation by upstream signals
   • PDHB subunit-specific contribution to phosphatase substrate not isolated
7. 2014 Medium

   How PDC stability is maintained beyond intrinsic assembly was unknown; PHD3 was identified as a physical PDHB interactor required to maintain PDC stability and activity, independent of subunit expression or phosphorylation, linking complex stability to hypoxic cell-death resistance.

   Evidence Proteomic interactor identification, Co-IP, PHD3 knockdown/knockout in MEFs and MCF7 cells with PDH activity assays and immunoblots

   PMID:25088999

   Open questions at the time

   • Hydroxylation site/mechanism on PDC not defined
   • Single lab
   • Direct vs indirect stabilization not fully resolved
8. 2018 Medium

   Whether PDHB levels actively shape the cancer glycolytic state was unknown; prolonged hypoxia durably reduced PDHB to sustain a Warburg-like state, and PDHB manipulation bidirectionally altered PDH activity and tumor growth in vivo.

   Evidence siRNA knockdown and stable overexpression in cancer cells, PDH activity assays, xenograft growth assays, metabolic profiling

   PMID:29436427

   Open questions at the time

   • Mechanism of durable suppression not defined
   • Single lab
9. 2017 Medium

   How PDHB is downregulated in cancer was partly unresolved; miR-146b-5p was shown to directly target the PDHB 3'-UTR, and PDHB re-expression reversed the miRNA's oncogenic effects on growth, invasion, and glycolysis.

   Evidence miRNA gain/loss-of-function, 3'-UTR luciferase reporter, PDHB rescue, growth/invasion/glycolysis assays, xenograft in colorectal cancer

   PMID:28560062

   Open questions at the time

   • Single lab
   • Other regulatory inputs not surveyed
10. 2025 Medium

    Non-canonical functions of PDHB were unknown; PDHB was found to bind glycolytic gene promoters (SLC2A1, GPI, PKM2) to drive their transcription and contribute to sorafenib resistance in HCC, with isoacteoside identified as an inhibitor.

    Evidence PDHB overexpression in HCC cells and xenografts, ChIP/promoter-binding assays, metabolic and drug-resistance assays, in vivo combination treatment

    PMID:39922943

    Open questions at the time

    • Mechanism of nuclear/chromatin localization of a mitochondrial enzyme not defined
    • Direct DNA binding vs co-factor recruitment not resolved
    • Single lab, abstract-level mechanistic detail
11. 2025 Medium

    A new PDHB stabilizing partner was identified; OGDHL physically interacts with PDHB in gastric cancer, and disrupting this interaction destabilizes PDHB, reduces pyruvate decarboxylation, and lowers acetyl-CoA/ATP, impairing proliferation.

    Evidence Co-IP for OGDHL–PDHB, RIP for miRNA–mRNA, immunoblot for PDHB stability, ELISA/ATP assays, siRNA knockdown, xenograft

    PMID:41420718

    Open questions at the time

    • Structural basis of OGDHL–PDHB interaction unknown
    • Reciprocal validation limited
    • Single lab
12. 2026 Medium

    Whether PDHB-derived energy metabolism feeds developmental chromatin programs was unknown; TGFβ-induced PDHB during endoderm differentiation supplies ATP that sustains BRG1/BAF chromatin remodeling and endodermal gene activation.

    Evidence PDHB disruption during hPSC endoderm differentiation, metabolic/OXPHOS/ATP assays, BRG1/BAF activity and chromatin accessibility assays, marker expression

    PMID:41702907

    Open questions at the time

    • Direct vs indirect link between ATP and BAF activity not fully isolated
    • Single lab, abstract-level detail
13. 2018 Medium

    The in vivo neuronal requirement for PDHB was tested; pan-neuronal knockdown of Drosophila PDHB shortened lifespan and impaired locomotion, NMJ morphology, mitochondrial integrity, and axon targeting, establishing its necessity for neuronal energy metabolism.

    Evidence Tissue-specific RNAi in Drosophila neurons, lifespan/locomotor assays, confocal imaging of NMJs and mitochondria, photoreceptor axon analysis

    PMID:29501567

    Open questions at the time

    • Drosophila model; human neuronal relevance inferred
    • Cell-autonomous metabolic cause vs developmental defect not fully separated

• How a canonically mitochondrial E1β subunit reaches gene promoters and whether its chromatin-associated and complex-stabilizing functions are mechanistically separable from its catalytic role remains unresolved.
• No structural model of PDHB on DNA
• Nuclear import/localization mechanism undefined
• Interplay between PHD3, OGDHL stabilization, and catalytic activity not integrated